CA3004296A1 - Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations - Google Patents

Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations Download PDF

Info

Publication number
CA3004296A1
CA3004296A1 CA3004296A CA3004296A CA3004296A1 CA 3004296 A1 CA3004296 A1 CA 3004296A1 CA 3004296 A CA3004296 A CA 3004296A CA 3004296 A CA3004296 A CA 3004296A CA 3004296 A1 CA3004296 A1 CA 3004296A1
Authority
CA
Canada
Prior art keywords
mscs
cells
donor
small
young
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3004296A
Other languages
English (en)
French (fr)
Inventor
Travis Block
Milos MARINKOVIC
Xiao-Dong Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3004296A1 publication Critical patent/CA3004296A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
CA3004296A 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations Abandoned CA3004296A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250664P 2015-11-04 2015-11-04
US62/250,664 2015-11-04
PCT/US2016/060624 WO2017079621A1 (en) 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

Publications (1)

Publication Number Publication Date
CA3004296A1 true CA3004296A1 (en) 2017-05-11

Family

ID=58662777

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3004296A Abandoned CA3004296A1 (en) 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

Country Status (8)

Country Link
US (1) US11802272B2 (https=)
EP (1) EP3370740A4 (https=)
JP (2) JP6871637B2 (https=)
CN (1) CN108601799A (https=)
AU (1) AU2016349701B2 (https=)
CA (1) CA3004296A1 (https=)
HK (1) HK1254739A1 (https=)
WO (1) WO2017079621A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153386A1 (en) * 2017-11-17 2019-05-23 James R. Musick Stem cell line for treatment of various medical conditions
KR20210072033A (ko) 2018-10-03 2021-06-16 스템바이오시스, 인크. 양수 세포-유래된 세포외 매트릭스 및 그의 용도
EP3927814A1 (en) 2019-02-21 2021-12-29 Stembiosys, Inc. Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069172A2 (en) * 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
WO2007067280A2 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Very small embryonic-like (vsel) stem cells and methods of isolating and using the same
US9155762B2 (en) * 2005-12-08 2015-10-13 University Of Louisville Research Foundation, Inc. Uses and isolation of stem cells from bone marrow
US8084023B2 (en) 2007-01-22 2011-12-27 The Board Of Trustees Of The University Of Arkansas Maintenance and propagation of mesenchymal stem cells
WO2010039241A1 (en) * 2008-09-30 2010-04-08 University Of Louisville Research Foundation, Inc. Methods for isolating very small embryonic-like (vsel) stem cells
WO2010114572A1 (en) 2009-03-31 2010-10-07 The Board Of Regents Of The University Of Texas System Isolation of human umbilical cord blood-derived mesenchymal stem cells
US9617511B2 (en) 2010-09-07 2017-04-11 The Board Of Regents Of The University Of Texas System Tissue-specific differentiation matrices and uses thereof
EP2694651A4 (en) 2011-04-01 2014-11-26 Univ Louisville Res Found METHOD AND COMPOSITIONS FOR THE LARGE INSULATION OF VERY SMALL EMBRYONAL-SIMILAR STEM CELLS
SI2785359T1 (sl) * 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US20170335286A1 (en) 2014-10-30 2017-11-23 Stembiosys, Inc. Methods for maintaining and expanding mesenchymal stem cells on extracellular matrix coated microcarriers

Also Published As

Publication number Publication date
JP2018537440A (ja) 2018-12-20
US20180320140A1 (en) 2018-11-08
JP7153951B2 (ja) 2022-10-17
AU2016349701B2 (en) 2023-10-19
US11802272B2 (en) 2023-10-31
JP2021105047A (ja) 2021-07-26
AU2016349701A1 (en) 2018-05-24
EP3370740A4 (en) 2019-05-22
CN108601799A (zh) 2018-09-28
JP6871637B2 (ja) 2021-05-12
EP3370740A1 (en) 2018-09-12
WO2017079621A1 (en) 2017-05-11
HK1254739A1 (zh) 2019-07-26

Similar Documents

Publication Publication Date Title
Kornicka et al. The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process
KR101507172B1 (ko) 동결된 제대조직으로부터 유래하는 생존가능한 세포
Wu et al. Age-related decline in the matrix contents and functional properties of human periodontal ligament stem cell sheets
US20220184136A1 (en) Highly functional manufactured abcb5+ mesenchymal stem cells
JP2010532370A (ja) 間葉系幹細胞の最適化増殖および移植のための方法および組成物
KR20080063406A (ko) 태반 줄기세포를 이용한 면역 조절
JP7153951B2 (ja) 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅
US20200270579A1 (en) Method for preparing dental pulp stem cells from cells derived from dental pulp tissue
DK2723850T3 (en) A method for culturing cells in the platelet lysate-containing medium
Emnett et al. Evaluation of tissue homogenization to support the generation of GMP‐compliant mesenchymal stromal cells from the umbilical cord
Huang et al. Establishment of a cytocompatible cell-free intervertebral disc matrix for chondrogenesis with human bone marrow-derived mesenchymal stromal cells
Alexander et al. Stromal cells cultivated from the choroid of human eyes display a mesenchymal stromal cell (MSC) phenotype and inhibit the proliferation of choroidal vascular endothelial cells in vitro
EP2732030B1 (en) Preparation of parental cell bank from foetal tissue
Labusca et al. Isolation and phenotypic characterisation of stem cells from late stage osteoarthritic mesenchymal tissues
Algraittee et al. Generation and Characterization of Human Osteoarthritis Cartilage-derived Mesenchymal Stem Cells by Modified Sample Processing and Culture Method.
Dabaghi et al. Allografts for partial meniscus repair: an in vitro and ex vivo meniscus culture study
US12441984B2 (en) Isolation, preservation, and expansion of canine umbilical cord mesenchymal stromal cells
Baptista et al. Processing of lipoaspirate samples for optimal mesenchymal stem cells isolation
Caprio et al. The Effect of Replacing Fetal Bovine Serum with Platelet Releasate on the Characterization of MSCs
Kim et al. Isolation and identification of mesenchymal stem cells from human mastoid bone marrow
Wang Vascularization and osteogenesis in bone physiological processes influenced by bio-active molecules and scaffolds
Ahmed Repairing injured articular cartilage: Investigation of potential mechanisms using mesenchymal stem cells
Sheard Screening and improving the safe provision of mesenchymal stem cells in regenerative medicine: an in vitro study
Scagliotti et al. Comparative analysis of multilineage properties of mesenchymal stromal cells derived from fetal sources shows an advantage of mesenchymal stromal cells isolated from cord blood in chondrogenic differentiation potential
Kornicka et al. Research Article The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230125